Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has entered into a global distribution agreement with Abcam plc (AIM: ABC; NASDAQ: ABCM) to sell the Group’s recently developed SARS-CoV-2 research ELISA Affimer® reagents.
Zyme Communications provides PR and marketing services for the life science sector. We support companies to raise their profile, build corporate value and generate interest from commercial leads, investors and partners.
Telephone: +44 (0)1223 968 920
Stirling House, Cambridge Innovation Park, Denny End Road, Waterbeach, Cambridge
Post Code: CB25 9QE
Country: United Kingdom
Membership Type: Corporate 6-20